Pneumagen is developing glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs).

Latest news

16 Sep, 2020
Pneumagen Announces Scientific Advisory Board and Development Team Appointments
27 May, 2020
Pneumagen Announces £4m fundraising and Commits to Clinical Trial Development for COVID-19
08 May, 2020
Pneumagen Ltd’s Recent COVID-19 Data Covered by BBC’s "The Nine"

Meet the team